It wouldn’t matter the total volume in sales .
It could be $10b . If retailers are cut to the bone
it’s a loss making exercise . The only winner
with Nuvaring Generic was First to Market.
So Scott gets it right this time. Even his statement
says affordable. It is to the consumer but like
all Generics now a Loss making exercise .
- Forums
- ASX - By Stock
- Ann: FDA approval of HALOETTE, a generic version of NUVARING
MYX
mayne pharma group limited
Add to My Watchlist
3.27%
!
$5.03

It wouldn’t matter the total volume in sales .It could be $10b ....
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M |
Open | High | Low | Value | Volume |
$5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14654 | $5.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.14 | 3111 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 5.010 |
2 | 61000 | 5.000 |
2 | 2200 | 4.990 |
2 | 702 | 4.970 |
3 | 2200 | 4.950 |
Price($) | Vol. | No. |
---|---|---|
5.140 | 3111 | 2 |
5.150 | 19052 | 1 |
5.180 | 396 | 1 |
5.200 | 2000 | 1 |
5.300 | 10000 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |